Skip to main content
Search
Audio Interview

Scale-up challenges in the production of nanomedicines from lab to industry

Published on May 29, 2023   31 min

Other Talks in the Playlist: Research and Clinical Interviews

Please wait while the transcript is being prepared...
0:00
Interviewer: Today I'm interviewing Prof. Dr. Oya Tagit, the team leader for BioInterfaces in the School of Life Sciences at the Institute of Chemistry and Bioanalytics, University of Applied Sciences and Arts Northwestern Switzerland, and executive board member of the Swiss Nanoscience Institute, on the subject of going from bench to industrial scale production of nanotherapeutics. Professor Tagit, thank you for spending the time for this interview. We all know that there are frequently challenges where one seeks to transition from lab-scale science to industrial production. May I start by asking first, for the purposes of this interview, what counts as nanoscale therapeutic? And what is the nature of the special challenges when scaling up their types and size? And of course what did we learn about the best way to meet those challenges, always remembering the constraints of time and cost, while meeting the requirements of regulators? What are the potential pitfalls and best practice approaches? Professor Tagit. Prof. Tagit: Thank you very much for your kind invitation and thank you for the questions. I need to break them apart to be more efficient and to be able to answer every piece. Let's start first with the definition of nano
Show
Hide

Scale-up challenges in the production of nanomedicines from lab to industry

Embed in course/own notes